- Conditions
- Extreme Prematurity, Enteral Nutrition, Bronchopulmonary Dysplasia
- Interventions
- High-energy group, Standard-energy group
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Day to 3 Days
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 6,730
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Cancer, Choroid Plexus Tumors
- Interventions
- Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and Trospium Chloride Capsules, Placebo Capsules
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
- Conditions
- Appetitive Behavior
- Interventions
- Lexicon training
- Behavioral
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma
- Interventions
- NC318
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more
- Conditions
- Fat Metabolism
- Interventions
- neuromuscular electrical stimulation
- Other
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Anxiety, Caregiver Burden
- Interventions
- Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years to 95 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Neoplasms, Melanoma
- Interventions
- Modakafusp Alfa, Pembrolizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Cancer Patients First-ever Acute Ischemic Stroke
- Interventions
- Enoxaparin, Aspirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Hydroxocobalamin Adverse Reaction
- Interventions
- Hydroxocobalamin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Racial/Ethnic Minorities on Dialysis
- Interventions
- Active Comparator: peer navigator, Placebo Comparator: Control Arm (standard of care)
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Kerendia (Finerenone, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more
- Conditions
- Recruitment
- Interventions
- Baseline (control) message, Positively-valenced message, Payment-inclusive message, Positively-valenced, payment-inclusive message
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pain and Anxiety
- Interventions
- VR Guided Meditation
- Device
- Lead sponsor
- Christopher Almario
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Interventions
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Interventions
- Clofarabine, Cytarabine intravenous, Methotrexate, Intrathecal (IT) Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Seattle, Washington
- Conditions
- Parenting, Child Behavior, Child Rearing
- Interventions
- Triple P-Level 2, Play Nicely, Usual care
- Other
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 1,133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders, Mental Disorders
- Interventions
- Growth Mindset Online Single-Session Program, Self-Kindness Online Single-Session Program, Supportive Therapy Online Single-Session Program (Control)
- Behavioral
- Lead sponsor
- Child Mind Institute
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- SYS6043
- Drug
- Lead sponsor
- Conjupro Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Obesity, Hyperphagia, Feeding and Eating Disorders
- Interventions
- Computer Based Response Training Weight Loss Intervention, Generic Response Training Control Intervention
- Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 18 Years to 38 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Breast Cancer
- Interventions
- Percutaneous Removal and Margin Ablation
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas